Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

SELL
$5.07 - $7.2 $193,674 - $275,040
-38,200 Reduced 70.48%
16,000 $96,000
Q4 2021

Feb 15, 2022

SELL
$5.67 - $8.54 $281,799 - $424,437
-49,700 Reduced 47.83%
54,200 $349,000
Q3 2021

Nov 16, 2021

SELL
$13.4 - $16.3 $194,300 - $236,350
-14,500 Reduced 12.25%
103,900 $1.43 Million
Q2 2021

Aug 16, 2021

BUY
$14.81 - $19.13 $1.15 Million - $1.49 Million
77,900 Added 192.35%
118,400 $1.76 Million
Q1 2021

May 18, 2021

SELL
$14.52 - $23.53 $53,724 - $87,061
-3,700 Reduced 8.37%
40,500 $721,000
Q4 2020

Feb 17, 2021

SELL
$10.14 - $15.19 $2.65 Million - $3.97 Million
-261,300 Reduced 85.53%
44,200 $631,000
Q3 2020

Nov 17, 2020

BUY
$9.57 - $21.32 $2.4 Million - $5.35 Million
251,100 Added 461.58%
305,500 $3.09 Million
Q2 2020

Aug 17, 2020

BUY
$12.21 - $16.99 $241,758 - $336,401
19,800 Added 57.23%
54,400 $801,000
Q1 2020

May 15, 2020

SELL
$9.03 - $19.72 $153,510 - $335,240
-17,000 Reduced 32.95%
34,600 $463,000
Q4 2019

Feb 14, 2020

BUY
$13.01 - $17.15 $671,316 - $884,939
51,600 New
51,600 $727,000
Q2 2019

Aug 15, 2019

SELL
$15.0 - $19.62 $211,500 - $276,642
-14,100 Closed
0 $0
Q1 2019

May 16, 2019

BUY
$11.65 - $17.72 $164,265 - $249,851
14,100 New
14,100 $245,000
Q4 2018

Feb 15, 2019

SELL
$10.72 - $16.73 $219,760 - $342,965
-20,500 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$17.73 - $26.69 $363,465 - $547,145
20,500 New
20,500 $500,000
Q2 2018

Aug 15, 2018

SELL
$10.79 - $24.44 $138,112 - $312,832
-12,800 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$9.0 - $20.16 $115,200 - $258,048
12,800 New
12,800 $143,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $684M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.